Simbionix's Innovative Solution for Patient Specific Simulation Receives Further Global Recognition - MyFoxTallahassee.com

Simbionix's Innovative Solution for Patient Specific Simulation Receives Further Global Recognition

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Simbionix USA Corporation

CLEVELAND, July 17, 2014 /PRNewswire/ --


Medical simulation technology provides an excellent approach to training physicians, nurses and allied health personnel. However, medical simulation development and utilization does not have to stop with training. Simbionix USA Corporation advances the concept of using its proprietary technologies and capabilities to turn the simulation experience into an essential part of pre-operative surgery planning.

     (Logo: http://photos.prnewswire.com/prnh/20120502/529202-a )

The company's revolutionary PROcedure Rehearsal Studio™ (PRS) steps up simulation by enabling physicians to rehearse a complete endovascular procedure on a virtual 3D anatomical model based on a specific patient's CT data. The virtual model can be used for simulating, analyzing and evaluating pre-operative surgical treatment options prior to performing an actual case, which may increase a physician's confidence in the upcoming procedure.

The advantages of patient specific planning have long been recognized in other fields within the healthcare industry, such as medical imaging. Simbionix is pleased to announce the signing of a collaboration agreement with the market leader in medical image analysis software, Pie Medical Imaging BV. The company manufactures and distributes the 3mensio software, a clinical application that enables the visualization and analysis of patient CT scans in both 2D and 3D modes.

The collaboration will enable exporting the 3mensio Vascular™ model into the Simbionix simulation environment to form a comprehensive planning solution that combines 3DR, data analysis and simulation on the same platform. The solution will allow physicians and clinical specialists to rehearse a procedure in a complete virtual environment without the need for physical tools. This will take users of the 3mensio software to the next level of preparedness for endovascular procedures, as it will allow added simulation insights. Cases created by the software may also be imported to the ANGIO Mentor simulator for full procedure practice using fluoroscopy, guidewires, catheters, and other equipment that is used in the cath lab.

Simbionix recently received the CE marking of conformity for its patient specific simulation, an important step towards launching this innovative technology and expansion of its use in the clinical practice. The PRS CE mark demonstrates the product's compliance with stringent requirements related to the quality, safety, and performance of medical devices determined by the European Union legislation.

In addition, Simbionix PRS has recently been granted a patent in China. The company now has patents for this technology in three key countries: the USA, UK and China. These patents represent recognition for Simbionix's comprehensive line of products, which provide innovative solutions to advance medical performance and ensure patient safety.

Gary Zamler, Simbionix CEO added that "Growing interest from the image analysis market, which 3mensio is part of, demonstrates the need for more comprehensive planning solutions. The ability to evaluate surgical treatment options using simulation anytime, anywhere, is a major factor in achieving the goal to increase patient safety and improve procedure outcomes. The collaboration agreement, CE mark and additional patent are all examples of the company's key position as a market leader and innovator in the field of medical simulation."

Visit: http://www.simbionix.com, FacebookTwitter and LinkedIn.

Contact: Rebecca Levy, Rebecca@simbionix.com, +1-216-2292040


©2012 PR Newswire. All Rights Reserved.